No products in the cart
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend (12mg)
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin peptides blend are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend
Studies have suggested that the highest output of growth hormone (GH) from the anterior pituitary gland can be attained through a combination of growth hormone-releasing hormone (GHRH) analog and agonist of growth hormone secretagogue receptor (GHSR). The combination of Ipamorelin with modified GRF is one of the various combinations which may help to achieve the above objective. Interestingly, more specific results appear to be achieved beyond the increase in GH synthesis through the refinement of the choice of GHRH analog, and GHSR agonist used. Modified GRF, also an effective GHRH analog may have effects beyond the improvement of GH release. It has appeared to benefit intestinal inflammation, wound healing, and cardiac function in animal models. The introduction of Ipamorelin along with modified GRF may trigger the highest expression of GH. Ipamorelin has the potential to improve bone growth and stabilization of the cellular matrix. The above physiological outcomes are in addition to the potential for improvement of bone development via increased GH release.
Fragment 176-191 Specifications
Molecular Formula: C78H125N23O23S2
Molecular Weight: 1817.1 g/mol
CAS Number: 66004-57-7
Mod GRF 1-29 Specifications
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
PubChem: CID 56841945
CAS Number: 863288-34-0
Molecular Formula: C38H49N9O5
Molecular Weight: 711.85 g/mol
PubChem: CID 9831659
CAS Number: 170851-70-4
Frag 176-191 & Mod GRF 1-29 & Ipamorelin – Research in Body Composition
The main area of study of this peptide blend has focused on its potential to promote fat loss and increase muscle mass. The critical component among this peptide blend capable of achieving weight loss is the Frag 176-191. HGH Fragment 176-191 is the main ‘lipolytic fragment.’ It acts on the beta-3 adrenergic receptors (ADRB3). This peptide has been suggested to lead to increased fat burning in fatty tissues and increased fat breakdown by triggering ‘thermogenesis’ (heat production) in skeletal muscles by acting on these receptors.
Researchers have noticed that knock-out mice without ADRB3 receptors cannot respond to the effects of Fragment 176-191. Interestingly, researchers noticed that Frag 176-191 only appeared to lead to weight loss in obese mice and did not affect lean mice. It was reported to lead to a nearly 50% reduction in weight gain in obese mice noticed over three weeks. Other elements of this blend, such as Mod GRF (1-29), have been studied in relation to improving body composition by increasing muscle mass. The apparent increase in muscle mass may be due to two mechanisms triggered by this peptide: muscle hypertrophy (increase in the size of muscle fibers) and muscle hyperplasia (increase in the number of muscle fibers).
Frag 176-191 & Mod GRF 1-29 & Ipamorelin – Research in Bone and Joint Health
This blend may be useful in dealing with various bone and joint-related conditions associated with aging. These include conditions such as osteoporosis and joint osteoarthritis. Researchers noticed that when HGH Frag 176-191 was used in conjunction with hyaluronic acid therapy in conditions such as osteoarthritis, it could potentiate joint cartilage growth. The study noticed that using the peptide in animal models of osteoarthritis appeared to improve joint cartilage. Studies reported that the apparent improvement was more marked when used in combination with hyaluronic acid. Kwon et al. concluded that “Intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA injections were more effective than HA or AOD9604 injections alone in the collagenase-induced knee OA rabbit model.” In addition, peptides such as Mod GRF 1-29 and Ipamorelin have been suggested to improve bone health by activating bone cells via GH-mediated pathways. The use of these peptides may lead to increased activity, proliferation, and differentiation of bone-forming cells and may also lead to an increase in Bone Mineral Density (BMD). This would be useful in conditions such as osteoporosis.
Frag 176-191 & Mod GRF 1-29 & Ipamorelin – Research in Anti-aging
The levels of growth hormone decline sharply following teenage years and continue to decline even more rapidly after the 40s. The signs of aging are the direct consequence of declining levels of GH. A blend of GH stimulating peptides, such as this one, may stimulate the natural increase in GH levels. An increase in GH levels is associated with an improvement in cell proliferation due to telomere shortening and a reduction in cellular death due to a decline in processes such as oxidative stress.
Frag 176-191 & Mod GRF 1-29 & Ipamorelin – General Research in Health
Researchers have suggested other potential health benefits of this peptide blend, including:
● Improved cardiovascular health and quicker recovery following Myocardial Infarction (MI)
● Improved gut health
● Improved healing following injury or surgery and better aesthetic outcomes following cosmetic surgery procedures
● Improved mental health and might be helpful in neurodegenerative diseases such as Alzheimer’s dementia and Parkinson’s disease
● Better overall health, energy, and vitality levels
● Mental well-being
● Better thyroid health
● Enhanced recovery following injury and post-workout
Research has suggested that Fragment 176-191, a synthetic GHRH agonist may be a strong catalyst for catabolism of adipocytes. Researchers even note that “in obese Zucker rats, daily treatment with an oral dose of AOD9604 for 19 days reduced over 50% body weight gain of the animals in comparison with the control.” Hence it may be possible to bring about targeted lipolysis by including Fragment 176-191 with Ipamorelin and Mod GRF 1-29. It would be more effective than most of the GHRH agonists in the burning of fat, and has been is popularly called a “lipolytic fragment.” Inclusion of Frag 176-191 appears to have the potential to improve fat metabolism on the premise of increased GH release and may modify physiological metabolism in favor of lean body mass.
- Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
- Ferrer-Lorente R, Cabot C, Fernández-López JA, Alemany M. Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats. Life Sci. 2005 Sep 2;77(16):2051-8. doi: 10.1016/j.lfs.2005.04.008. PMID: 15935402.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.
- Waters MJ, Brooks AJ. Growth hormone and cell growth. Endocr Dev. 2012;23:86-95. doi: 10.1159/000341761. Epub 2012 Nov 23. PMID: 23182823.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.